Supported by an independent educational grant from Jazz Pharmaceuticals, Inc.

Posters

Patient Perspective on Barriers to Diagnosis and Treatment of Tardive Dyskinesia: Results From a Cross-Sectional Survey

Tardive dyskinesia (TD) is a hyperkinetic movement disorder resulting from chronic exposure to antipsychotics.

All Posters

Balancing Efficacy and Safety in Patients With Tardive Dyskinesia Treated With Deutetrabenazine by Investigating Exposure–Response Relationships

Deutetrabenazine (DTBZ) is used for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease.

Real-World Evidence of Patient Experience With Once-Daily Deutetrabenazine Extended-Release Tablets for Tardive Dyskinesia and Chorea in Huntington Disease in the United States

Deutetrabenazine is approved by the United States Food and Drug Administration for treatment of tardive dyskinesia (TD) and chorea in Huntington disease (HD).

Early Response With Valbenazine and Long-Term Symptom Reduction in Patients With Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study

Valbenazine is approved for the treatment of tardive dyskinesia (TD), a persistent and disabling movement disorder associated with prolonged antipsychotic exposure.

Randomized Withdrawal Study Design to Evaluate the Persistence of the Therapeutic Effect of Deutetrabenazine in the Treatment of Tardive Dyskinesia

The long-term open-label extension study of rollover subjects (n=343) from the ARM-TD and AIM-TD trials evaluating the safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesi

Comparison of Safety and Tolerability of Deutetrabenazine During Titration and Maintenance in Patients With Tardive Dyskinesia

Deutetrabenazine is approved to treat tardive dyskinesia (TD) in adults and is titrated weekly based on dyskinesia control and tolerability.

Onset and Resolution of Key Adverse Events in Valbenazine-Treated Patients with Tardive Dyskinesia: Pooled Post Hoc Analyses from Two Long-Term Clinical Trials

Tardive dyskinesia (TD) is a persistent and potentially disabling movement disorder associated with prolonged exposure to antipsychotics and other dopamine receptor blocking agents.

Understanding the evolving continuing medical education needs of physicians managing patients with TD

This study sought to understand the evolving continuing medical education (CME) needs of physicians managing patients with tardive dyskinesia (TD).

TD360: Outcomes of a Tardive Dyskinesia Educational Curriculum – A Focus on Quality of Life, Increased Detection and Novel Treatments

Best practices in Tardive Dyskinesia (TD) identification and management among psychiatry and neurology clinicians have historically been suboptimal.

Use Of VMAT2 Inhibitors For Tardive Dyskinesia In Geriatric Populations - A Case Study

Geriatric populations are at increased risk of developing tardive dyskinesia as they age, leading to increased risk of injuries secondary to resulting impairments in gait and balance.